Eiichi Araki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4341974/publications.pdf Version: 2024-02-01



ЕПСНІ Аракі

#	Article	IF	CITATIONS
1	New classification and diagnostic criteria for insulin resistance syndrome. Endocrine Journal, 2022, 69, 107-113.	0.7	5
2	New classification and diagnostic criteria for insulin resistance syndrome. Diabetology International, 2022, 13, 337-343.	0.7	5
3	Factors Affecting Human Damage in Heavy Rains and Typhoon Disasters. Tohoku Journal of Experimental Medicine, 2022, 256, 175-185.	0.5	2
4	Dietary intake and physical activity in Japanese patients with type 2 diabetes: the Japan Diabetes Complication and its Prevention prospective study (JDCP study 8). Diabetology International, 2022, 13, 344-357.	0.7	2
5	<scp>Longâ€term</scp> efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled <scp>52â€week</scp> outcomes from the <scp>DEPICT</scp> â€1 and â€2 studies. Diabetes, Obesity and Metabolism, 2021, 23, 549-560.	2.2	21
6	Rapid and dramatic glucoseâ€lowering effect of bromocriptine in an inadequately controlled typeÂ2 diabetes patient with prolactinoma. Journal of Diabetes Investigation, 2021, 12, 668-671.	1.1	3
7	Hypoglycemia Induces Mitochondrial Reactive Oxygen Species Production Through Increased Fatty Acid Oxidation and Promotes Retinal Vascular Permeability in Diabetic Mice. Antioxidants and Redox Signaling, 2021, 34, 1245-1259.	2.5	14
8	A homogeneous assay to determine high-density lipoprotein subclass cholesterol in serum. Analytical Biochemistry, 2021, 613, 114019.	1.1	4
9	Clinical profiles of hyperglycemic crises: A singleâ€center retrospective study from Japan. Journal of Diabetes Investigation, 2021, 12, 1359-1366.	1.1	3
10	Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. Diabetology International, 2021, 12, 1-51.	0.7	6
11	Longâ€term (52â€week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the <scp>DEPICT</scp> â€2 study. Diabetes, Obesity and Metabolism, 2021, 23, 1496-1504.	2.2	6
12	The Amount of Residual Incretin Regulates the Pancreatic β-cell Function and Glucose Homeostasis. Internal Medicine, 2021, 60, 1433-1442.	0.3	0
13	Activation of heat shock response improves biomarkers of NAFLD in patients with metabolic diseases. Endocrine Connections, 2021, 10, 521-533.	0.8	3
14	Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized doubleâ€blind placeboâ€controlled clinical trials. Cardiovascular Diabetology, 2021, 20, 96.	2.7	16
15	Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the <scp>PIONEER</scp> 1, 3, 4 and 8 trials. Diabetes, Obesity and Metabolism, 2021, 23, 2785-2794.	2.2	7
16	Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate. Journal of Atherosclerosis and Thrombosis, 2021, 28, 974-996.	0.9	10
17	Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). BMJ Open Diabetes Research and Care, 2021, 9, e001787.	1.2	15
18	Questionnaire Survey Regarding Troubles and Concerns Related to Clinical Research Based on the Clinical Trial Act for Clinicians and Academics. Kurume Medical Journal, 2021, , .	0.0	0

EIICHI ARAKI

#	Article	IF	CITATIONS
19	Atypical pituitary abscess lacking rim enhancement and diffusion restriction with an unusual organism, <i>Moraxella catarrhalis</i> : A case report and review of the literature. , 2021, 12, 617.		3
20	Clinical Features of Patients With Acute Aortic Dissection After an Earthquake: Experience from the Kumamoto Earthquake 2016. American Journal of Hypertension, 2020, 33, 261-268.	1.0	6
21	Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICTâ€5): 52â€week results from a randomized, openâ€label, phase III clinical trial. Diabetes, Obesity and Metabolism, 2020, 22, 540-548.	2.2	22
22	Impact of tissue macrophage proliferation on peripheral and systemic insulin resistance in obese mice with diabetes. BMJ Open Diabetes Research and Care, 2020, 8, e001578.	1.2	4
23	Mild electrical stimulation with heat shock attenuates renal pathology in adriamycin-induced nephrotic syndrome mouse model. Scientific Reports, 2020, 10, 18719.	1.6	0
24	Japanese Clinical Practice Guideline for Diabetes 2019. Journal of Diabetes Investigation, 2020, 11, 1020-1076.	1.1	159
25	Japanese Clinical Practice Guideline for Diabetes 2019. Diabetology International, 2020, 11, 165-223.	0.7	266
26	Baseline Plasma Aldosterone Level and Renin Activity Allowing Omission of Confirmatory Testing in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1990-e1998.	1.8	7
27	Brown adipocyte-derived exosomal miR-132-3p suppress hepatic Srebf1 expression and thereby attenuate expression of lipogenic genes. Biochemical and Biophysical Research Communications, 2020, 530, 500-507.	1.0	20
28	Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions. Biochemical and Biophysical Research Communications, 2020, 524, 8-15.	1.0	9
29	New perspectives on insulin therapy. Journal of Diabetes Investigation, 2020, 11, 795-797.	1.1	0
30	Longâ€ŧerm efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the <scp>DEPICT</scp> â€2 study): 52â€week results from a randomized controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 1516-1526.	2.2	38
31	Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes ― A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society ―. Circulation Journal, 2020, 85, 82-125.	0.7	16
32	Clinical Features of Disaster-Associated Direct Deaths during Recent Inland Earthquakes in Japan. Tohoku Journal of Experimental Medicine, 2020, 251, 169-173.	0.5	5
33	with Diabetes. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 419-426.	0.0	1
34	ç³—å°;ç—…è ç™,ã,¬ã,≇f‰ãf©ã,≇f³2019. The Journal of the Japanese Society of Internal Medicine, 2020, 109,	9 45.0 50.	0

35	Impacts of the 2016 Kumamoto Earthquake on glycemic control in patients with diabetes. Journal of Diabetes Investigation, 2019, 10, 521-530.	1.1	11
36	Superior efficacy with a fixedâ€ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulinâ€naÀ ve Japanese patients with type 2 diabetes in a phase 3, openâ€label, randomized trial. Diabetes, Obesity and Metabolism, 2019, 21, 2674-2683.	2.2	15

EIICHI ARAKI

#	Article	IF	CITATIONS
37	Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. International Journal of Molecular Sciences, 2019, 20, 5537.	1.8	27
38	Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naA ⁻ ve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study. Endocrine Journal, 2019, 66, 745-752.	0.7	10
39	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care, 2019, 42, 2262-2271.	4.3	146
40	Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal–Bolus Therapy. Diabetes Therapy, 2019, 10, 1347-1356.	1.2	4
41	Mineralocorticoid Receptor May Regulate Glucose Homeostasis through the Induction of Interleukin-6 and Glucagon-Like peptide-1 in Pancreatic Islets. Journal of Clinical Medicine, 2019, 8, 674.	1.0	4
42	Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPARÎ ³ . Atherosclerosis, 2019, 286, 30-39.	0.4	12
43	Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52â€week data from the PROVIDE study. Diabetes, Obesity and Metabolism, 2019, 21, 1737-1744.	2.2	35
44	FoxK1 and FoxK2 in insulin regulation of cellular and mitochondrial metabolism. Nature Communications, 2019, 10, 1582.	5.8	57
45	Hyperemesis gravidarum followed by refeeding syndrome causes electrolyte abnormalities induced rhabdomyolysis and diabetes insipidus. Endocrine Journal, 2019, 66, 253-258.	0.7	6
46	Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment. International Journal of Molecular Sciences, 2019, 20, 706.	1.8	53
47	Impact of hepatic HSP72 on insulin signaling. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E305-E318.	1.8	12
48	Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 876-882.	2.2	18
49	Effects of a novel selective peroxisome proliferatorâ€activated receptorâ€Î± modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. Journal of Diabetes Investigation, 2018, 9, 1323-1332.	1.1	32
50	Japanese Clinical Practice Guideline for Diabetes 2016. Journal of Diabetes Investigation, 2018, 9, 657-697.	1.1	158
51	The clinical course and pathophysiological investigation of adolescent gestational diabetes insipidus: a case report. BMC Endocrine Disorders, 2018, 18, 4.	0.9	8
52	Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. Diabetes Care, 2018, 41, 538-546.	4.3	122
53	Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. Journal of Atherosclerosis and Thrombosis, 2018, 25, 521-538.	0.9	97
54	Efficacy and safety of pemafibrate (K-877), aÂselective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. Journal of Clinical Lipidology, 2018, 12, 173-184.	0.6	127

		Ειιςηι Αγακι		
#	Article		IF	Citations
55	Efficacy of Pemafibrate on Atherogenic Dyslipidemia: Results of a Pooled Analysis of Pen II/III Clinical Trials Compared with Placebo. Atherosclerosis Supplements, 2018, 32, 25-2	nafibrate Phase 6.	1.2	1
56	Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipic patients with atherogenic dyslipidemia. Journal of Clinical Lipidology, 2018, 12, 1267-12	lemia in 179.e4.	0.6	35
57	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Dia	betes (the) Tj ETQq1 1 0.	784314 rg 4.3	BT/Overloci
58	Japanese Clinical Practice Guideline for Diabetes 2016. Diabetology International, 2018,	9, 1-45.	0.7	215
59	A Rare Case of Thyrotropin-Secreting Pituitary Adenoma Coexisting with Papillary Thyroi Presenting with Visual Disturbance without Hyperthyroidism. World Neurosurgery, 2018	d Carcinoma 3, 119, 394-399.	0.7	1
60	Impacts of tight multifactorial intervention in patients with type 2 diabetes: Implications Japan Diabetes Outcome Intervention Trial 3. Journal of Diabetes Investigation, 2018, 9,	s from the 1022-1024.	1.1	1
61	Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Con Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2291-2301.	trolled Trial.	1.8	225
62	Identification of microRNA that represses IRS-1 expression in liver. PLoS ONE, 2018, 13,	e0191553.	1.1	37
63	8. Recent Advances in the Treatment of Diabetes. The Journal of the Japanese Society of Medicine, 2018, 107, 1865-1873.	Internal	0.0	0
64	Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated recepto (SPPARMα), in combination with statin treatment: Two randomised, double-blind, place clinical trials in patients with dyslipidaemia. Atherosclerosis, 2017, 261, 144-152.	r α modulator bo-controlled	0.4	101
65	Low glucose induces mitochondrial reactive oxygen species via fatty acid oxidation in bo endothelial cells. Journal of Diabetes Investigation, 2017, 8, 750-761.	ovine aortic	1.1	33
66	Causes of death in Japanese patients with diabetes based on the results of a survey of 4 during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus Diabetes Investigation, 2017, 8, 397-410.	5,708 cases 5. Journal of	1.1	95
67	Impaired balance is related to the progression of diabetic complications in both young a adults. Journal of Diabetes and Its Complications, 2017, 31, 1275-1282.	nd older	1.2	19
68	New glycemic targets for patients with diabetes from the Japan Diabetes Society. Journa Investigation, 2017, 8, 123-125.	I of Diabetes	1.1	48
69	Efficacy and safety of dapagliflozin over 1 year as addâ€on to insulin therapy in <sc patients with type 2 diabetes: the <scp>DAISY</scp> (Dapagliflozin Added to patients u</sc 	p>Japanese inder InSulin) Tj ETQq1 1	0. 22 4314	rg B T /Overic
70	Effect of an intensified multifactorial intervention on cardiovascular outcomes and mort 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 951-964.	ality in type	5.5	228
71	Causes of death in Japanese patients with diabetes based on the results of a survey of 4 during 2001–2010: report of Committee on Causes of Death in Diabetes Mellitus. Dia International, 2017, 8, 117-136.	5,708 cases betology	0.7	49
72	Acetate alters expression of genes involved in beige adipogenesis in 3T3-L1 cells and ob Journal of Clinical Biochemistry and Nutrition, 2016, 59, 207-214.	ese KK-Ay mice.	0.6	53

Ειιςηι Αγακι

#	Article	IF	CITATIONS
73	Non-invasive measurement of skin autofluorescence to evaluate diabetic complications. Journal of Clinical Biochemistry and Nutrition, 2016, 58, 135-140.	0.6	32
74	The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 1279-1282.	2.2	8
75	Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis, 2016, 249, 36-43.	0.4	146
76	A 1â€year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study). Journal of Diabetes Investigation, 2016, 7, 703-710.	1.1	19
77	Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16â€week doubleâ€blind treatment period. Journal of Diabetes Investigation, 2016, 7, 555-564.	1.1	42
78	New glycemic targets for patients with diabetes from the Japan Diabetes Society. Diabetology International, 2016, 7, 327-330.	0.7	6
79	Activation of heat shock response to treat obese subjects with type 2 diabetes: a prospective, frequency-escalating, randomized, open-label, triple-arm trial. Scientific Reports, 2016, 6, 35690.	1.6	10
80	Hyperglycemia Induces Cellular Hypoxia through Production of Mitochondrial ROS Followed by Suppression of Aquaporin-1. PLoS ONE, 2016, 11, e0158619.	1.1	85
81	Coexistence of resistance to thyroid hormone and papillary thyroid carcinoma. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, 160003.	0.2	6
82	Cellular stress response pathways and diabetes mellitus. Diabetology International, 2015, 6, 239-242.	0.7	0
83	Statins meditate anti-atherosclerotic action in smooth muscle cells by peroxisome proliferator-activated receptor-Î ³ activation. Biochemical and Biophysical Research Communications, 2015, 457, 23-30.	1.0	24
84	Mitochondrial reactive oxygen species in the pathogenesis of early diabetic nephropathy. Journal of Diabetes Investigation, 2015, 6, 137-139.	1.1	41
85	A rare case showing subacute thyroiditis-like symptoms with amyloid goiter after anti-tumor necrosis factor therapy. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 140117.	0.2	8
86	Abstract 12384: Novel Approach to Residual Risk, K-877, a Potent and Selective PPAR-α Modulator (SPPARMα), Added-on to Pitavastatin in Japanese Patients With Dyslipidemia. Circulation, 2015, 132, .	1.6	0
87	Comparison of the efficacy of sitagliptin and glimepiride doseâ€up in <scp>J</scp> apanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination. Journal of Diabetes Investigation, 2014, 5, 320-326.	1.1	7
88	Mild Electrical Stimulation with Heat Shock Reduces Visceral Adiposity and Improves Metabolic Abnormalities in Subjects with Metabolic Syndrome or Type 2 Diabetes: Randomized Crossover Trials. EBioMedicine, 2014, 1, 80-89.	2.7	22
89	SIRT7 Controls Hepatic Lipid Metabolism by Regulating the Ubiquitin-Proteasome Pathway. Cell Metabolism, 2014, 19, 712-721.	7.2	173
90	Mild Electrical Stimulation Increases Stress Resistance and Suppresses Fat Accumulation via Activation of LKB1-AMPK Signaling Pathway in C. elegans. PLoS ONE, 2014, 9, e114690.	1.1	13

Eiichi Araki

#	Article	IF	CITATIONS
91	Evaluation of a new device for measurement of hemoglobin A1c for Japanese subjects. Diabetology International, 2013, 4, 112-116.	0.7	1
92	Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes. Cardiovascular Diabetology, 2013, 12, 160.	2.7	27
93	Insulin receptor activation through its accumulation in lipid rafts by mild electrical stress. Journal of Cellular Physiology, 2013, 228, 439-446.	2.0	19
94	Mechanismâ€based antioxidant therapies promise to prevent diabetic complications?. Journal of Diabetes Investigation, 2013, 4, 105-107.	1.1	9
95	Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation, 2012, 3, 179-184.	1.1	12
96	Thiazolidinedioneâ€independent activation of peroxisome proliferatorâ€activated receptor γ is a potential target for diabetic macrovascular complications. Journal of Diabetes Investigation, 2012, 3, 11-23.	1.1	2
97	International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Journal of Diabetes Investigation, 2012, 3, 39-40.	1.1	731
98	Hyperthermia With Mild Electrical Stimulation Protects Pancreatic Î ² -Cells From Cell Stresses and Apoptosis. Diabetes, 2012, 61, 838-847.	0.3	43
99	The PREDICTIVETM Study: a multinational, prospective observational study to evaluate the safety and efficacy of insulin detemir treatment in patients with type 1 and 2 diabetes—data from the Japan cohort. Diabetology International, 2012, 3, 11-20.	0.7	1
100	International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetology International, 2012, 3, 8-10.	0.7	202
101	HbA _{1c} : The lower the better?. Journal of Diabetes Investigation, 2011, 2, 45-47.	1.1	0
102	Telmisartan Exerts Antiatherosclerotic Effects by Activating Peroxisome Proliferator-Activated Receptor-Î ³ in Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1268-1275.	1.1	40
103	Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetology International, 2010, 1, 2-20.	0.7	322
104	Nifedipine Induces Peroxisome Proliferator-Activated Receptor-Î ³ Activation in Macrophages and Suppresses the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1598-1605.	1.1	36
105	An acylic polyisoprenoid derivative, geranylgeranylacetone protects against visceral adiposity and insulin resistance in high-fat-fed mice. American Journal of Physiology - Endocrinology and Metabolism, 2010, 299, E764-E771.	1.8	25
106	Heat shock treatment with mild electrical stimulation safely reduced inflammatory markers in healthy male subjects. Obesity Research and Clinical Practice, 2010, 4, e101-e109.	0.8	14
107	Predictors of coronary heart disease in Japanese patients with type 2 diabetes: Screening for coronary artery stenosis using multidetector computed tomography. Journal of Diabetes Investigation, 2010, 1, 50-55.	1.1	4
108	Oxidative stress: A cause and therapeutic target of diabetic complications. Journal of Diabetes Investigation, 2010, 1, 90-96.	1.1	109

Ειιςηι Αγακι

#	Article	IF	CITATIONS
109	Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Journal of Diabetes Investigation, 2010, 1, 212-228.	1.1	1,206
110	TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis. Biochemical and Biophysical Research Communications, 2009, 379, 43-48.	1.0	74
111	Mild Electrical Stimulation Increases Ubiquitinated Proteins and Hsp72 in A549 Cells via Attenuation of Proteasomal Degradation. Journal of Pharmacological Sciences, 2008, 108, 222-226.	1.1	25
112	Mild Electrical Stimulation with Heat Shock Ameliorates Insulin Resistance via Enhanced Insulin Signaling. PLoS ONE, 2008, 3, e4068.	1.1	66
113	Statins Activate Peroxisome Proliferator-Activated Receptor γ Through Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase–Dependent Cyclooxygenase-2 Expression in Macrophages. Circulation Research, 2007, 100, 1442-1451.	2.0	214
114	Troglitazone inhibits oxidized low-density lipoprotein-induced macrophage proliferation: Impact of the suppression of nuclear translocation of ERK1/2. Atherosclerosis, 2007, 191, 22-32.	0.4	13
115	Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes, 2006, 55, 120-7.	0.3	215
116	Enhanced expression of PDX-1 and Ngn3 by exendin-4 during β cell regeneration in STZ-treated mice. Biochemical and Biophysical Research Communications, 2005, 327, 1170-1178.	1.0	84
117	Genome-wide linkage analysis of type 2 diabetes mellitus reconfirms the susceptibility locus on 11p13–p12 in Japanese. Journal of Human Genetics, 2004, 49, 629-634.	1.1	18
118	Evaluation of Urinary 8-Hydroxydeoxy-Guanosine as a Novel Biomarker of Macrovascular Complications in Type 2 Diabetes. Diabetes Care, 2003, 26, 1507-1512.	4.3	173
119	Impact of Endoplasmic Reticulum Stress Pathway on Pancreatic β-Cells and Diabetes Mellitus. Experimental Biology and Medicine, 2003, 228, 1213-1217.	1.1	161
120	Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Research and Clinical Practice, 2000, 48, 201-210.	1.1	91
121	Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research and Clinical Practice, 1995, 28, 103-117.	1.1	2,814